|
1
|
Stinchcombe TE and Socinski MA:
Considerations for second-line therapy of non-small cell lung
cancer. Oncologist. 13(Suppl 1): 28–36. 2008.
|
|
2
|
Chen XL, Hu HJ, Pan YQ, et al: Molecular
mechanism of acquisiton of invasion and metastasis phenotype in
human lung cancer cell line A549/DDP. J Mod Oncol. 21:1670–1674.
2013.
|
|
3
|
Lu LS: Relationship between cancer
metastasis and drug resistance. J Int Oncol. 33:665–667. 2006.
|
|
4
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: a promising target in solid tumours. Cancer Treat
Rev. 30:1–17. 2004.
|
|
5
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001.
|
|
6
|
Veale D, Kerr N, Gibson GJ, Kelly PJ and
Harris AL: The relationship of quantitative epidermal growth factor
receptor expression in non-small cell lung cancer to long term
survival. Br J Cancer. 68:162–165. 1993.
|
|
7
|
Schmidt M and Lichtner RB: EGF receptor
targeting in therapy-resistant human tumors. Drug Resist Updat.
5:11–18. 2002.
|
|
8
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007.
|
|
9
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003.
|
|
10
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158.
2003.
|
|
11
|
Giaccone G, Herbst RS, Manegold C, et al:
Gefitinib in combination with gemcitabine and cisplatin in advanced
non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin
Oncol. 22:777–784. 2004.
|
|
12
|
Herbst RS, Giaccone G, Schiller JH, et al:
Gefitinib in combination with paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a phase III trial - INTACT 2.
J Clin Oncol. 22:785–794. 2004.
|
|
13
|
Fry DW, Kraker AJ, McMichael A, et al: A
specific inhibitor of the epidermal growth factor receptor tyrosine
kinase. Science. 265:1093–1095. 1994.
|
|
14
|
Ward WH, Cook PN, Slater AM, Davies DH,
Holdgate GA and Green LR: Epidermal growth factor receptor tyrosine
kinase. Investigation of catalytic mechanism, structure-based
searching and discovery of a potent inhibitor. Biochem Pharmacol.
48:659–666. 1994.
|
|
15
|
Lui VW, Boehm AL, Koppikar P, et al:
Antiproliferative mechanisms of a transcription factor decoy
targeting signal transducer and activator of transcription (STAT)
3: the role of STAT1. Mol Pharmacol. 71:1435–1443. 2007.
|
|
16
|
Wu X, Zhu Y, Yan H, et al: Isothiocyanates
induce oxidative stress and suppress the metastasis potential of
human non-small cell lung cancer cells. BMC Cancer. 10:2692010.
|
|
17
|
Guo L, Li L, Wang W, Pan Z, Zhou Q and Wu
Z: Mitochondrial reactive oxygen species mediates nicotine-induced
hypoxia-inducible factor-1α expression in human non-small cell lung
cancer cells. Biochim Biophys Acta. 1822:852–861. 2012.
|
|
18
|
Johnson JL, Pillai S, Pernazza D, Sebti
SM, Lawrence NJ and Chellappan SP: Regulation of matrix
metalloproteinase genes by E2F transcription factors: Rb-Raf-1
interaction as a novel target for metastatic disease. Cancer Res.
72:516–526. 2012.
|
|
19
|
Hiraishi Y, Wada T, Nakatani K, et al:
EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell
carcinoma cell lines. Pathol Oncol Res. 14:39–43. 2008.
|
|
20
|
Sorenson CM and Eastman A: Mechanism of
cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2
arrest and DNA double-strand breaks. Cancer Res. 48:4484–4488.
1988.
|
|
21
|
Sorenson CM, Barry MA and Eastman A:
Analysis of events associated with cell cycle arrest at G2 phase
and cell death induced by cisplatin. J Natl Cancer Inst.
82:749–755. 1990.
|
|
22
|
Knudsen ES and Wang JY: Targeting the
RB-pathway in cancer therapy. Clin Cancer Res. 16:1094–1099.
2010.
|
|
23
|
Li J, Ran C, Li E, et al: Synergistic
function of E2F7 and E2F8 is essential for cell survival and
embryonic development. Dev Cell. 14:62–75. 2008.
|
|
24
|
Cobrinik D: Pocket proteins and cell cycle
control. Oncogene. 24:2796–2809. 2005.
|
